Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

142.28 +0.32 (+0.23%)
Official Closing Price Updated: 7:00 PM EDT, Jun 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,992,092
Open 141.87
Bid (Size) 142.32 (4)
Ask (Size) 142.68 (1)
Prev. Close 141.96
Today's Range 141.51 - 142.66
52wk Range 75.56 - 144.50
Shares Outstanding N/A
Dividend Yield 1.24%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wegovy, Ozempic Maker Novo Nordisk To Invest $4.1B In US Manufacturing, Doubling Plant Size To Meet Surging Demand For Weight Loss Drugs
Novo Nordisk A/S is set to invest $4.1 billion in expanding its U.S. manufacturing operations to meet the increasing demand for its weight loss drugs. 
Via Benzinga
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
Regeneron Pharmaceuticals released data from a Phase 1 study on garetosmab and trevogrumab at the ADA meeting, showing significant increases in lean mass and reductions in fat mass in healthy... 
Via Benzinga

Performance

YTD
+39.34%
+39.34%
1 Month
+6.12%
+6.12%
3 Month
+10.25%
+10.25%
6 Month
+38.57%
+38.57%
1 Year
+80.99%
+80.99%

More News

Read More
Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'
Via Benzinga
Exposures Product Safety
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
Via InvestorPlace
7 Strong Buy Blue-Chip Stocks to Keep You in the Green
Via InvestorPlace
Novo Nordisk's Wegovy Demonstrates Greater Weight Loss In Women With Heart Condition
Via Benzinga
3 Biotech Stocks to Buy Now: June 2024
Via InvestorPlace
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
Lawsuit Could Challenge Trust In Ozempic And Other Popular Weight Loss Drugs
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
The Best Could Be Yet to Come for Novo Nordisk and Ozempic
Via The Motley Fool
Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss
Via Benzinga
Nestle Carefully Targets Weight-Loss Drug Users with New Food Line
Via Benzinga
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Via Benzinga
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Via Benzinga
7 Stocks With Impressive Earnings Growth: Real or Engineered?
Via InvestorPlace
Eli Lilly Hits All-Time High, Named To Big Cap 20 List: Check These Lists For Best Stocks To Buy
Via Investor's Business Daily
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
Via Benzinga
Obesity In Children - US Parents Face Tough Time To Access Recommended Treatment, Though Novo Nordisk's Drug Still Sees Strong Demand
Via Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
Via The Motley Fool
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
Via Investor's Business Daily
Could Structure Therapeutics Become the Next Novo Nordisk?
Via The Motley Fool
3 Best Stocks to Buy From the Fantastic 5
Via InvestorPlace
Week Of June 16: What's In Store For The Markets
Via Talk Markets
Where Will Madrigal Pharmaceuticals Be in 3 Years?
Via The Motley Fool
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.